David Thomas
Garvan Institute of Medical Research, NSW, Australia
- This delegate is presenting an abstract at this event.
Professor David Thomas is an NHMRC Senior Research Fellow, and a medical oncologist specialising in sarcomas. He has recently been appointed as Director of the Kinghorn Cancer Centre and Head of Cancer Division at the Garvan Institute of Medical Research in Sydney.
Dr Thomas has a particular focus on the impact of genomics on cancer medicine. His current basic research interests include quantitative evolutionary genetics in cancer cell populations, mapping a cancer neochromosome at single nucleotide resolution, and understanding the in vivo biology of osteosarcoma. His work has had significant translational impact. Dr Thomas led an international clinical trial of denosumab in Giant Cell Tumor of bone, which has led to a new therapeutic option for patients with advanced disease. He established a national infrastructure for clinical research into sarcomas, the Australasian Sarcoma Study Group. As Director of the statewide adolescent and young adult cancer service, onTrac@PeterMac, Dr Thomas played a significant national and international role in the development of adolescent and young adult oncology.
Presentations this author is a contributor to:
Rapid fluorodeoxyglucose-positron emission tomography (FDG-PET) response to denosumab treatment in patients with giant cell tumour of bone (GCTB): results from two phase 2 trials (#416)
3:00 PM
David Thomas
Poster discussion 2
What drives the cost of cancer treatment? Insights from an analysis of a longitudinal cohort (Cancer 2015) linked to administrative reimbursement data (#67)
4:45 PM
Paula Lorgelly
Best of the Best Orals - Health services
Pulmonary oligometastatic sarcoma (#9)
11:50 AM
David Thomas
Concurrent session - Current evidence in the management of secondary disease